Bio-Vascular suffers Peri-Strips set-back:
This article was originally published in Clinica
Medicare reimbursement for Bio-Vascular's Peri-Strips has ceased pending an evaluation of the product's safety and efficacy by the technical assessment committee of the Health Care Financing Administration. Peri-Strips is used in lung volume reduction surgery (LVR), generating some 40% of the company's turnover. Surgeons are asked to submit LVR results by February 13th. It is expected that data on several hundred cases will be submitted. A decision by the committee is not expected before mid-April at the earliest, says Bio-Vascular's CEO John Karcanes.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.